IGF2BP2 and hepatocellular carcinoma: Among them, compound 4 (IC50 = 18.2–35.5 μM), compound 6 (IC50 = 42.9–52.6 μM), and compound 9 (IC50 = 24.9–39.8 μM) demonstrate higher activity and effectively kill IGF2BP2-containing colorectal cancer and hepatocellular carcinoma cells in vitro and in vivo [115].